Description: Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Home Page: www.pyxisoncology.com
PYXS Technical Analysis
35 Cambridgepark Drive
Cambridge,
MA
02140
United States
Phone:
617 221 9059
Officers
| Name | Title |
|---|---|
| Mr. John L. Flavin M.B.A., MBA, Ph.D. | Co-Founder & Independent Chairman |
| Dr. Lara S. Sullivan M.D., MBA | CEO, Pres & Director |
| Ms. Pamela Yanchik Connealy M.B.A. | Chief Financial Officer |
| Dr. Jay M. Feingold M.D., Ph.D. | Chief Medical Officer |
| Mr. Jitendra Wadhane | Chief Accounting Officer, Sr. VP of Fin. & Corp. Controller |
| Dr. Balu N. Balasubramanian Ph.D. | Interim Chief Technology Officer |
| Dr. Jan Pinkas Ph.D. | Chief Scientific Officer |
| Ms. Martina Molsbergen B.S. | Interim Chief Bus. Officer |
| Dr. Charles T. Gombar Ph.D. | Sr. VP of Portfolio & Program Management |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2176 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-10-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 73 |